Which statin drug is best for lowering risk of heart attack, stroke, and all cause mortality in higher risk patients?
The recently published LODESTAR randomized trial directly compared Rosuvastatin (Crestor) and Atorvastatin (Lipitor) head to head.
Here are the results:
“Conclusions: In adults with coronary artery disease, rosuvastatin and atorvastatin showed comparable efficacy for the composite outcome of all cause death, myocardial infarction, stroke, or any coronary revascularisation at three years. Rosuvastatin was associated with lower LDL cholesterol levels but a higher risk of new onset diabetes mellitus requiring antidiabetics and cataract surgery compared with atorvastatin.”
This trial was run in 12 hospitals in South Korea, September 2016 to November 2019 in 4400 adults (age ≥19 years) with coronary artery disease. Participants were assigned to receive either rosuvastatin (n=2204) or atorvastatin (n=2196) using 2×2 factorial randomisation. The primary outcome was a three year composite of all cause death, myocardial infarction, stroke, or any coronary revascularisation.



